NCT05301530: Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. |
|
|
| Completed | 1 | 50 | RoW | Faceptor, NNG-TMAB, Trastazumab, Herceptin, Trastuzumab, Docetaxel, Taxotere | Nanogen Pharmaceutical Biotechnology Joint Stock Company, Vietstar Biomedical Research, MedProve Inc | Breast Cancer Metastatic, Breast Cancer Female, Breast Cancer Recurrent | 08/20 | 02/21 | | |
